Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 58
States / cities: Scottsdale, Arizona • Bryant, Arkansas • Rogers, Arkansas + 51 more

Conditions: Alzheimer Disease, Progressive Supranuclear Palsy
Interventions: Not listed
Lead sponsor: KineMed; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Glendale, California • Eatontown, New Jersey • San Antonio, Texas

Conditions: Subarachnoid Hemorrhage
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Peri-implantitis
Interventions: Gingival Crevicular Fluid Sampling; Procedure
Lead sponsor: Christopher Barwacz; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Urinary Incontinence, Nocturia
Interventions: Exercise-based behavioral therapy, Behavioral control; Behavioral
Lead sponsor: Atlanta VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Birmingham, Alabama • Decatur, Georgia

Conditions: Knee Arthroscopy, General Anesthesia, Subarachnoid Block
Interventions: General anesthesia, Subarachnoid block; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 30 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Opioid-use Disorder
Interventions: XR-B (SUBLOCADETM), XR-NTX; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: New Haven, Connecticut • Baltimore, Maryland • Hanover, New Hampshire + 3 more

Conditions: Pain
Interventions: 4% lidocaine, 3.5% ophthalmic lidocaine gel; Drug
Lead sponsor: Miami VA Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Sepsis, Fluid Overload, Hypovolemia
Interventions: Ultrasound and NICOM; Device
Lead sponsor: Olive View-UCLA Education & Research Institute; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Sylmar, California

Conditions: PCV, Polypoidal Choroidal Vasculopathy
Interventions: high-dose ranibizumab, ranibizumab; Drug
Lead sponsor: Hawaii Pacific Health; Other
Eligibility: 25 Years to 95 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Honolulu, Hawaii • ‘Aiea, Hawaii

Conditions: Hot Weather; Adverse Effect, Kidney Dysfunction, Kidney Injury, Hyperthermia, Dehydration
Interventions: Fluid replacement, No fluid replacement; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 44 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Graft Vs Host Disease, Vitamin A Deficiency, Vitamin D Deficiency
Interventions: Vitamin A, Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Tampa, Florida • Buffalo, New York • Columbus, Ohio

Conditions: Alzheimer's Disease
Interventions: Albutein 5%, Control; Biological · Other
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Whiting, New Jersey

Conditions: Abdominal Aortic Aneurysm (AAA)
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hyperthermic Intraperitoneal
Interventions: Allon System; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metabolic Syndrome, Healthy Participants, Metabolically Healthy Obesity, Metabolically Abnormal Obesity
Interventions: inulin; Dietary Supplement
Lead sponsor: Ball State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Muncie, Indiana

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: Fludarabine Phosphate, Tacrolimus, Thiotepa, Total-Body Irradiation (TBI), Magnetic Affinity Cell Sorting, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation; Drug · Radiation · Other + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 14 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Seattle, Washington

Conditions: 3D Transesophageal and Transthoracic Echocardiogram
Interventions: transesophageal echocardiography (TEE), thermodilution, transthoracic echocardiography (TTE); Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Subjects
Interventions: EDG-7500, Placebo; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Smoking, Asthma, Electronic Cigarette Use, Cigarette Smoking
Interventions: Nicotine; Other
Lead sponsor: Brown University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hematopoietic Organs; Disorder
Interventions: Lactobacillus plantarum strains 299 and 299v; Drug
Lead sponsor: Columbia University; Other
Eligibility: 2 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Jacksonville, Florida • St. Petersburg, Florida • New York, New York

Conditions: Healthy Volunteer
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pleural Effusions
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Esophageal Stricture
Interventions: Budesonide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

Evaluation of Cerebral Spinal Fluid and Blood in Patients With Subarachnoid Hemorrhage

A Comparison of Inflammatory Mediators Surrounding Titanium or Zirconium Implant Abutments

Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease

Patient Satisfaction and Postoperative Analgesia Between Subarachnoid Block With 2-chloroprocaine Versus General Anesthesia for Knee Arthroscopy

Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye

Comparison of Non-Invasive Methods of Assessing Fluid Responsiveness in ED and ICU Patients

Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)

Renal Considerations in the Heat Stress Recommendations (Aim2)

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

ACZ885 for the Treatment of Abdominal Aortic Aneurysm

Use of Water Warming/Cooling Garment to Maintain a Constant Intraoperative Core Target Temperature in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Proof-of-Concept Study

Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Left Ventricular Volume and Ejection Fraction: Validation of Real Time 3 Dimensional Transesophageal Echocardiography

A Study of EDG-7500 in Healthy Adults

E-cigarettes for Harm Reduction in Adults With Asthma

Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55

A Study to Establish the Diagnostic Value of the EPISEEK-MPE Liquid Biopsy Assay to Identify Cancer in Pleural Effusion Samples.

Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy